Key points are not available for this paper at this time.
Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Masahiro Tsuboi
Roy S. Herbst
Thomas John
New England Journal of Medicine
University of California, Los Angeles
The University of Melbourne
Shanghai Jiao Tong University
Building similarity graph...
Analyzing shared references across papers
Loading...
Tsuboi et al. (Sun,) studied this question.
www.synapsesocial.com/papers/6941cf2d6ff23261fafbb7c7 — DOI: https://doi.org/10.1056/nejmoa2304594